Clinical and Virologic Efficacy of Herpes Simplex Virus Type 2 Suppression by Acyclovir in a Multicontinent Clinical Trial
Clinical and Virologic Efficacy of Herpes Simplex Virus Type 2 Suppression by Acyclovir in a Multicontinent Clinical Trial
复制标题
DOI：
10.1086/651381
复制
发表时间：
2010-04-15
影响因子：
6.4
通讯作者：
Wald, Anna
中科院分区：
文献类型：
--
作者：
Fuchs, Jonathan;Celum, Connie;Wald, Anna
阿昔洛韦抑制治疗（400毫克，每日两次）减少单纯疱疹病毒（HSV）2型相关的生殖器溃疡疾病和病变HSV脱落。在一项关于阿昔洛韦抑制HSV 2型以预防人类免疫缺陷病毒（HIV）感染的国际试验（HIV预防试验网络039）中，与美国男性相比，阿昔洛韦对非洲女性和秘鲁男性生殖器溃疡疾病的发生率以及对HSV DNA损伤的发生率和数量的影响较小。观察到的阿昔洛韦抑制HSV的临床和病毒学疗效的区域差异，需要进一步评估阿昔洛韦反应的决定因素。（ClinicalTrials.gov标识符：NCT 00076232。）
Acyclovir suppressive therapy (400 mg twice daily) reduces herpes simplex virus (HSV) type 2-associated genital ulcer disease and lesional HSV shedding. In an international trial of acyclovir for suppression of HSV type 2 to prevent human immunodeficiency virus (HIV) acquisition (HIV Prevention Trials Network 039), acyclovir had a smaller effect on the frequency of genital ulcer disease as well as a smaller effect on the frequency and quantity of lesional HSV DNA in African women and Peruvian men, compared with its effects in men in the United States. The observed regional variation in the clinical and virologic efficacy of acyclovir for HSV suppression warrants further evaluation of determinants of responses to acyclovir. (ClinicalTrials.gov identifier: NCT00076232.)